Generic Name and Formulations:
Ocriplasmin 2.5mg/mL; per vial; soln for intravitreal inj after dilution; contains mannitol; preservative- and latex-free.
Indications for JETREA:
Treatment of symptomatic vitreomacular adhesion.
Give by intravitreal inj. 0.125mg (0.1mL of the diluted soln) once as a single dose to the affected eye.
For ophthalmic intravitreal inj only. Monitor for elevation in intraocular pressure immediately after inj. Monitor for decreased vision. Repeated administration in the same eye: not recommended. Treatment in the other eye is not recommended within 7 days of the initial inj. Pregnancy (Cat.C). Nursing mothers.
Vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, retinal edema; intraocular inflammation/infection/hemorrhage, increased intraocular pressure, yellowish vision.
Single-use vial (0.2mL)—1
Psychiatry Advisor Articles
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression
- New Study Compares Opioid Dependence Relapse Treatments
- Increase Use of Nursing Home for Patients With Cognitive Impairment Category
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder